Oragenics (OGEN) Non Operating Income (2011 - 2026)
Oragenics' (OGEN) quarterly Non Operating Income came in at $32059.0 in Q1 2026, up 116.81% YoY from $14787.0 in Q1 2025, and down 56.98% on a QoQ basis from $74521.0 in Q4 2025.
Oragenics (OGEN) Non Operating Income (2011 - 2026) Analysis & Trends
Oragenics (OGEN) has 16 years of Non Operating Income data on file, last reported at $32059.0 in Q1 2026.
- Quarterly Non Operating Income rose 116.81% year-over-year to $32059.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$394069.0 (down 88.43% YoY) and the FY2025 annual result came in at -$616894.0, down 6676.82% from the prior year.
- Non Operating Income fell to $32059.0 in Q1 2026, from $74521.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $81561.0 in Q3 2023 to a low of -$557833.0 in Q2 2025.
- A 5-year average of -$12522.4 and a median of $32059.0 in 2026 frame the typical range for Non Operating Income.
- The widest YoY moves for Non Operating Income: up 1081.19% in 2025, down 61400.33% in 2025.
- Tracing OGEN's Non Operating Income over 5 years: stood at $61427.0 in 2022, then fell by 20.4% to $48895.0 in 2023, then sank by 87.1% to $6309.0 in 2024, then surged by 1081.19% to $74521.0 in 2025, then sank by 56.98% to $32059.0 in 2026.
- The last three Non Operating Income figures came in at $32059.0 (Q1 2026), $74521.0 (Q4 2025), and $57184.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -53.64 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -51.63 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Oragenics | 2.38 Mn | 2.38 Mn | - | 17,444.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17,444.00 |
| Mar 31, 2026 | 32,059.00 |
| Dec 31, 2025 | 74,521.00 |
| Sep 30, 2025 | 57,184.00 |
| Jun 30, 2025 | -557,833.00 |
| Mar 31, 2025 | -190,766.00 |
| Dec 31, 2024 | 6,309.00 |
| Sep 30, 2024 | -25,590.00 |
| Jun 30, 2024 | 910.00 |
| Mar 31, 2024 | 9,270.00 |
| Dec 31, 2023 | 48,895.00 |
| Sep 30, 2023 | 81,561.00 |
| Jun 30, 2023 | 58,732.00 |
| Mar 31, 2023 | 59,978.00 |
| Dec 31, 2022 | 61,427.00 |
| Sep 30, 2022 | 36,406.00 |
| Jun 30, 2022 | 14,922.00 |
| Mar 31, 2022 | 19,134.00 |
| Dec 31, 2021 | 8,539.00 |
| Sep 30, 2021 | 10,709.00 |